{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T21:11:27Z","timestamp":1785791487512,"version":"3.56.0"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","award":["ECF171156"],"award-info":[{"award-number":["ECF171156"]}],"id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","award":["CDF171126"],"award-info":[{"award-number":["CDF171126"]}],"id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","award":["CDF171147"],"award-info":[{"award-number":["CDF171147"]}],"id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1140447"],"award-info":[{"award-number":["1140447"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001184","name":"Cure Cancer Australia Foundation","doi-asserted-by":"publisher","award":["1086449"],"award-info":[{"award-number":["1086449"]}],"id":[{"id":"10.13039\/501100001184","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001026","name":"National Breast Cancer Foundation","doi-asserted-by":"publisher","award":["-19-048"],"award-info":[{"award-number":["-19-048"]}],"id":[{"id":"10.13039\/501100001026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001026","name":"National Breast Cancer Foundation","doi-asserted-by":"publisher","award":["2010632"],"award-info":[{"award-number":["2010632"]}],"id":[{"id":"10.13039\/501100001026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001026","name":"National Breast Cancer Foundation","doi-asserted-by":"publisher","award":["APP1146599"],"award-info":[{"award-number":["APP1146599"]}],"id":[{"id":"10.13039\/501100001026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.phrs.2023.106806","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T12:38:42Z","timestamp":1685018322000},"page":"106806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Innovative thiosemicarbazones that induce multi-modal mechanisms to down-regulate estrogen-, progesterone-, androgen- and prolactin-receptors in breast cancer"],"prefix":"10.1016","volume":"193","author":[{"given":"Faten","family":"Shehadeh-Tout","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heloisa H.","family":"Milioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraya","family":"Roslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patric J.","family":"Jansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahendiran","family":"Dharmasivam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinny","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tharushi","family":"Wijesinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahan Gholam","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Des R.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaklina","family":"Kovacevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2023.106806_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.phrs.2023.106806_bib2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1586\/eem.11.25","article-title":"Progesterone receptor action: defining a role in breast cancer","volume":"6","author":"Daniel","year":"2011","journal-title":"Expert Rev. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2023.106806_bib3","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1186\/bcr3599","article-title":"Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide","volume":"16","author":"Cochrane","year":"2014","journal-title":"Breast Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2023.106806_bib4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ajpath.2012.09.021","article-title":"The prolactin receptor transactivation domain is associated with steroid hormone receptor expression and malignant progression of breast cancer","volume":"182","author":"Fiorillo","year":"2013","journal-title":"Am. J. Pathol."},{"issue":"9","key":"10.1016\/j.phrs.2023.106806_bib5","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.tem.2015.08.002","article-title":"Progesterone receptor-estrogen receptor crosstalk: a novel insight","volume":"26","author":"Thomas","year":"2015","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2023.106806_bib6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.steroids.2016.09.004","article-title":"Progesterone induces progesterone receptor gene (PGR) expression via rapid activation of protein kinase pathways required for cooperative estrogen receptor alpha (ER) and progesterone receptor (PR) genomic action at ER\/PR target genes","volume":"114","author":"Diep","year":"2016","journal-title":"Steroids"},{"issue":"1","key":"10.1016\/j.phrs.2023.106806_bib7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mce.2011.09.020","article-title":"Interplay between progesterone and prolactin in mammary development and implications for breast cancer","volume":"357","author":"Lee","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"issue":"1","key":"10.1016\/j.phrs.2023.106806_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.trecan.2015.12.001","article-title":"Targeting androgen\/estrogen receptors crosstalk in cancer","volume":"2","author":"Karamouzis","year":"2016","journal-title":"Trends Cancer"},{"issue":"8","key":"10.1016\/j.phrs.2023.106806_bib9","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/PAI.0000000000000234","article-title":"Expression of androgen receptor in estrogen receptor-positive breast cancer","volume":"24","author":"Agrawal","year":"2016","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.phrs.2023.106806_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.steroids.2016.06.007","article-title":"Nuclear and extranuclear-initiated estrogen receptor signaling crosstalk and endocrine resistance in breast cancer","volume":"114","author":"Kulkoyluoglu","year":"2016","journal-title":"Steroids"},{"issue":"3","key":"10.1016\/j.phrs.2023.106806_bib11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.6026\/97320630012135","article-title":"S et al.: molecular mechanisms and mode of tamoxifen resistance in breast cancer","volume":"12","author":"Ali","year":"2016","journal-title":"Bioinformation"},{"issue":"1","key":"10.1016\/j.phrs.2023.106806_bib12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40487-017-0046-2","article-title":"A review of fulvestrant in breast cancer","volume":"5","author":"Nathan","year":"2017","journal-title":"Oncol. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2023.106806_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0039-128X(02)00110-1","article-title":"Estrogen receptor phosphorylation","volume":"68","author":"Lannigan","year":"2003","journal-title":"Steroids"},{"issue":"5","key":"10.1016\/j.phrs.2023.106806_bib14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1677\/JME-08-0103","article-title":"Non-classical genomic estrogen receptor (ER)\/specificity protein and ER\/activating protein-1 signaling pathways","volume":"41","author":"Safe","year":"2008","journal-title":"J. Mol. Endocrinol."},{"issue":"8","key":"10.1016\/j.phrs.2023.106806_bib15","doi-asserted-by":"crossref","DOI":"10.1007\/s00018-013-1376-3","article-title":"Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy","volume":"71","author":"Zhou","year":"2014","journal-title":"Cell. Mol. Life Sci.: CMLS"},{"issue":"4","key":"10.1016\/j.phrs.2023.106806_bib16","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1210\/me.2004-0486","article-title":"Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes","volume":"19","author":"Bjornstrom","year":"2005","journal-title":"Mol. Endocrinol."},{"issue":"2","key":"10.1016\/j.phrs.2023.106806_bib17","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202002279R","article-title":"Breaking the cycle: targeting of NDRG1 to inhibit bi-directional oncogenic cross-talk between pancreatic cancer and stroma","volume":"35","author":"Geleta","year":"2021","journal-title":"FASEB J."},{"issue":"4","key":"10.1016\/j.phrs.2023.106806_bib18","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1124\/mol.111.073627","article-title":"Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer","volume":"80","author":"Kovacevic","year":"2011","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.phrs.2023.106806_bib19","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1182\/blood-2004-03-0868","article-title":"Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment","volume":"104","author":"Yuan","year":"2004","journal-title":"Blood"},{"issue":"40","key":"10.1016\/j.phrs.2023.106806_bib20","doi-asserted-by":"crossref","first-page":"14901","DOI":"10.1073\/pnas.0604979103","article-title":"A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics","volume":"103","author":"Whitnall","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"17","key":"10.1016\/j.phrs.2023.106806_bib21","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1158\/0008-5472.CAN-11-1218","article-title":"Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes","volume":"71","author":"Lovejoy","year":"2011","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.phrs.2023.106806_bib22","doi-asserted-by":"crossref","first-page":"7230","DOI":"10.1021\/jm300768u","article-title":"Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo","volume":"55","author":"Lovejoy","year":"2012","journal-title":"J. Med Chem."},{"issue":"9","key":"10.1016\/j.phrs.2023.106806_bib23","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1182\/blood-2004-05-1866","article-title":"Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation","volume":"104","author":"Le","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2023.106806_bib24","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.freeradbiomed.2019.05.020","article-title":"Pharmacological targeting and the diverse functions of the metastasis suppressor, NDRG1, in cancer","volume":"157","author":"Park","year":"2020","journal-title":"Free Radic. Biol. Med"},{"issue":"3","key":"10.1016\/j.phrs.2023.106806_bib25","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1074\/jbc.M115.689653","article-title":"The metastasis suppressor, N-myc downstream-regulated gene-1 (NDRG1), down-regulates the ErbB family of receptors to inhibit downstream oncogenic signaling pathways","volume":"291","author":"Kovacevic","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.phrs.2023.106806_bib26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/emmm.201100190","article-title":"N\u2010myc downstream regulated gene 1 modulates Wnt\u2010\u03b2\u2010catenin signalling and pleiotropically suppresses metastasis","volume":"4","author":"Liu","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.phrs.2023.106806_bib27","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1038\/sj.onc.1207734","article-title":"Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression","volume":"23","author":"Bandyopadhyay","year":"2004","journal-title":"Oncogene"},{"issue":"31","key":"10.1016\/j.phrs.2023.106806_bib28","doi-asserted-by":"crossref","first-page":"12772","DOI":"10.1074\/jbc.R117.776393","article-title":"Interplay of the iron-regulated metastasis suppressor NDRG1 with epidermal growth factor receptor (EGFR) and oncogenic signaling","volume":"292","author":"Menezes","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.phrs.2023.106806_bib29","doi-asserted-by":"crossref","first-page":"11511","DOI":"10.1096\/fj.201903167R","article-title":"Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance","volume":"34","author":"Lim","year":"2020","journal-title":"FASEB J."},{"issue":"6","key":"10.1016\/j.phrs.2023.106806_bib30","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/carcin\/bgy178","article-title":"The metastasis suppressor, NDRG1, attenuates oncogenic TGF-beta and NF-kappaB signaling to enhance membrane E-cadherin expression in pancreatic cancer cells","volume":"40","author":"Menezes","year":"2019","journal-title":"Carcinogenesis"},{"issue":"17","key":"10.1016\/j.phrs.2023.106806_bib31","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1128\/MCB.00350-08","article-title":"Polyubiquitination of prolactin receptor stimulates its internalization, postinternalization sorting, and degradation via the lysosomal pathway","volume":"28","author":"Varghese","year":"2008","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.phrs.2023.106806_bib32","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.phrs.2015.08.013","article-title":"The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the \"Triad of Death\" in cancer by Di-2-pyridylketone thiosemicarbazones","volume":"100","author":"Jansson","year":"2015","journal-title":"Pharm. Res"},{"issue":"2","key":"10.1016\/j.phrs.2023.106806_bib33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1023\/B:BREA.0000025406.31193.e8","article-title":"Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen","volume":"85","author":"Johnson","year":"2004","journal-title":"Breast Cancer Res Treat."},{"key":"10.1016\/j.phrs.2023.106806_bib34","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/1471-2199-8-110","article-title":"Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells","volume":"8","author":"Guo","year":"2007","journal-title":"BMC Mol. Biol."},{"issue":"10","key":"10.1016\/j.phrs.2023.106806_bib35","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1021\/acs.jmedchem.6b00238","article-title":"Zinc(II)-thiosemicarbazone complexes are localized to the lysosomal compartment where they transmetallate with copper ions to induce cytotoxicity","volume":"59","author":"Stacy","year":"2016","journal-title":"J. Med Chem."},{"issue":"5","key":"10.1016\/j.phrs.2023.106806_bib36","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1124\/mol.115.103044","article-title":"Targeting the metastasis suppressor, N-Myc downstream regulated gene-1, with novel di-2-pyridylketone thiosemicarbazones: suppression of tumor cell migration and cell-collagen adhesion by inhibiting focal adhesion kinase\/paxillin signaling","volume":"89","author":"Wangpu","year":"2016","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.phrs.2023.106806_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101608","article-title":"Targeting Wnt\/tenascin C-mediated cross talk between pancreatic cancer cells and stellate cells via activation of the metastasis suppressor NDRG1","volume":"298","author":"Geleta","year":"2022","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.phrs.2023.106806_bib38","first-page":"685","article-title":"The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell","volume":"54","author":"Richardson","year":"1994","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.phrs.2023.106806_bib39","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s00394-015-0930-1","article-title":"Sensitization of estrogen receptor-positive breast cancer cell lines to 4-hydroxytamoxifen by isothiocyanates present in cruciferous plants","volume":"55","author":"Pawlik","year":"2016","journal-title":"Eur. J. Nutr."},{"issue":"3","key":"10.1016\/j.phrs.2023.106806_bib40","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3892\/etm.2011.226","article-title":"Analysis of estrogen receptor isoforms and variants in breast cancer cell lines","volume":"2","author":"Al-Bader","year":"2011","journal-title":"Exp. Ther. Med."},{"issue":"Suppl 4","key":"10.1016\/j.phrs.2023.106806_bib41","article-title":"Does tamoxifen change oestrogen and progesterone receptor expression in the endometrium and breast?","volume":"36","author":"Karck","year":"2000","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.phrs.2023.106806_bib42","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.1074\/jbc.M110090200","article-title":"Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells","volume":"277","author":"Richer","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2023.106806_bib43","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0022-4731(89)90368-3","article-title":"Tamoxifen decreases the estradiol induced progesterone receptors by interfering with nuclear estrogen receptor accumulation","volume":"33","author":"Castellano-Diaz","year":"1989","journal-title":"J. Steroid Biochem"},{"issue":"4","key":"10.1016\/j.phrs.2023.106806_bib44","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/pr.57.4.2","article-title":"The evolution of iron chelators for the treatment of iron overload disease and cancer","volume":"57","author":"Kalinowski","year":"2005","journal-title":"Pharm. Rev."},{"issue":"5","key":"10.1016\/j.phrs.2023.106806_bib45","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1073\/pnas.96.5.1858","article-title":"Proteasome-dependent degradation of the human estrogen receptor","volume":"96","author":"Nawaz","year":"1999","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.phrs.2023.106806_bib46","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1073\/pnas.97.3.1032","article-title":"Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome","volume":"97","author":"Lange","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.phrs.2023.106806_bib47","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2478\/s11658-006-0011-9","article-title":"Degradation and beyond: control of androgen receptor activity by the proteasome system","volume":"11","author":"Jaworski","year":"2006","journal-title":"Cell. Mol. Biol. Lett."},{"issue":"4","key":"10.1016\/j.phrs.2023.106806_bib48","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1083\/jcb.201210077","article-title":"Development of proteasome inhibitors as research tools and cancer drugs","volume":"199","author":"Goldberg","year":"2012","journal-title":"J. Cell Biol."},{"issue":"5","key":"10.1016\/j.phrs.2023.106806_bib49","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00018-002-8470-2","article-title":"Human estrogen receptor-\u03b1: regulation by synthesis, modification and degradation","volume":"59","author":"Reid","year":"2002","journal-title":"Cell. Mol. Life Sci. CMLS"},{"issue":"11","key":"10.1016\/j.phrs.2023.106806_bib50","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1158\/0008-5472.CAN-07-0967","article-title":"Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents","volume":"67","author":"Duong","year":"2007","journal-title":"Cancer Res"},{"issue":"14","key":"10.1016\/j.phrs.2023.106806_bib51","first-page":"1001","article-title":"The MDM2-p53 interaction","volume":"1","author":"Moll","year":"2003","journal-title":"Mol. Cancer Res."},{"issue":"3","key":"10.1016\/j.phrs.2023.106806_bib52","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ccr.2014.01.021","article-title":"Mutant p53 in cancer: new functions and therapeutic opportunities","volume":"25","author":"Muller","year":"2014","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.phrs.2023.106806_bib53","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1093\/carcin\/bgg042","article-title":"Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21(CIP1\/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation","volume":"24","author":"Le","year":"2003","journal-title":"Carcinogenesis"},{"issue":"10","key":"10.1016\/j.phrs.2023.106806_bib54","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/carcin\/bgg116","article-title":"The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1","volume":"24","author":"Liang","year":"2003","journal-title":"Carcinogenesis"},{"issue":"10","key":"10.1016\/j.phrs.2023.106806_bib55","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1158\/1078-0432.CCR-05-1962","article-title":"17\u03b2-estradiol induces down-regulation of Cap43\/NDRG1\/Drg-1, a putative differentiation-related and metastasis suppressor gene, in human breast cancer cells","volume":"12","author":"Fotovati","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2023.106806_bib56","article-title":"M: Regulation of estrogen receptor-alpha expression by the tumor suppressor gene p53 in MCF-7","volume":"vol. 180","author":"Angeloni","year":"2004","journal-title":"cells"},{"issue":"5","key":"10.1016\/j.phrs.2023.106806_bib57","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0960-0760(00)00108-4","article-title":"Estrogen receptor pathways to AP-1","volume":"74","author":"Kushner","year":"2000","journal-title":"J. Steroid Biochem Mol. Biol."},{"issue":"14","key":"10.1016\/j.phrs.2023.106806_bib58","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/onc.2011.370","article-title":"Macrophage-elicited loss of estrogen receptor-alpha in breast cancer cells via involvement of MAPK and c-Jun at the ESR1 genomic locus","volume":"31","author":"Stossi","year":"2012","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.phrs.2023.106806_bib59","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/nrc1209","article-title":"AP-1: a double-edged sword in tumorigenesis","volume":"3","author":"Eferl","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2023.106806_bib60","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0167-8140(98)00007-3","article-title":"The role of the stress-activated protein kinase (SAPK\/JNK) signaling pathway in radiation-induced apoptosis","volume":"47","author":"Verheij","year":"1998","journal-title":"Radio. Oncol."},{"issue":"22","key":"10.1016\/j.phrs.2023.106806_bib61","doi-asserted-by":"crossref","first-page":"6510","DOI":"10.1021\/jm0606342","article-title":"Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity","volume":"49","author":"Richardson","year":"2006","journal-title":"J. Med Chem."},{"issue":"3","key":"10.1016\/j.phrs.2023.106806_bib62","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1210\/me.2003-0105","article-title":"Fos and Jun inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site","volume":"18","author":"Petz","year":"2004","journal-title":"Mol. Endocrinol."},{"issue":"1\u20132","key":"10.1016\/j.phrs.2023.106806_bib63","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.mce.2013.03.004","article-title":"Transcriptional activity of c-Jun is critical for the suppression of AR function","volume":"372","author":"Hsu","year":"2013","journal-title":"Mol. Cell Endocrinol."},{"key":"10.1016\/j.phrs.2023.106806_bib64","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrc2695","article-title":"Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family","volume":"9","author":"Xu","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2023.106806_bib65","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/bcr2886","article-title":"NF-\u03baB, stem cells and breast cancer: the links get stronger","volume":"13","author":"Shostak","year":"2011","journal-title":"Breast Cancer Res."},{"issue":"2","key":"10.1016\/j.phrs.2023.106806_bib66","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10549-012-2090-9","article-title":"Estrogen receptor beta binds Sp1 and recruits a corepressor complex to the estrogen receptor alpha gene promoter","volume":"134","author":"Bartella","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.phrs.2023.106806_bib67","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.matbio.2013.09.002","article-title":"Cross-talk between estradiol receptor and EGFR\/IGF-IR signaling pathways in estrogen-responsive breast cancers: focus on the role and impact of proteoglycans","volume":"35","author":"Skandalis","year":"2014","journal-title":"Matrix Biol."},{"issue":"3","key":"10.1016\/j.phrs.2023.106806_bib68","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/bcr55","article-title":"Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer","volume":"2","author":"Biscardi","year":"2000","journal-title":"Breast Cancer Res."},{"issue":"2","key":"10.1016\/j.phrs.2023.106806_bib69","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/cdd.2013.116","article-title":"Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ER\u03b1+ tumorigenesis","volume":"21","author":"Chan","year":"2014","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.phrs.2023.106806_bib70","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12885-018-3993-6","article-title":"Leptin-induced ER-\u03b1-positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK\/AKT\/STAT-pathway","volume":"18","author":"Haque","year":"2018","journal-title":"BMC Cancer"},{"issue":"5241","key":"10.1016\/j.phrs.2023.106806_bib71","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1126\/science.270.5241.1491","article-title":"Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase","volume":"270","author":"Kato","year":"1995","journal-title":"Science"},{"issue":"6331","key":"10.1016\/j.phrs.2023.106806_bib72","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1126\/science.aah6893","article-title":"PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D","volume":"355","author":"Toska","year":"2017","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.phrs.2023.106806_bib73","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12282-007-0026-8","article-title":"Tyrosine1248-phosphorylated HER2 expression and HER2 gene amplification in female invasive ductal carcinomas","volume":"15","author":"Taniyama","year":"2008","journal-title":"Breast Cancer"},{"issue":"40","key":"10.1016\/j.phrs.2023.106806_bib74","doi-asserted-by":"crossref","first-page":"24747","DOI":"10.1016\/S0021-9258(17)31455-2","article-title":"Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product","volume":"269","author":"Kim","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.phrs.2023.106806_bib75","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.tibs.2006.03.009","article-title":"MAPK signal specificity: the right place at the right time","volume":"31","author":"Murphy","year":"2006","journal-title":"Trends Biochem Sci."},{"issue":"1","key":"10.1016\/j.phrs.2023.106806_bib76","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ccr.2013.06.002","article-title":"Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer","volume":"24","author":"Vaillant","year":"2013","journal-title":"Cancer Cell"},{"issue":"20","key":"10.1016\/j.phrs.2023.106806_bib77","doi-asserted-by":"crossref","first-page":"10162","DOI":"10.1158\/0008-5472.CAN-05-4111","article-title":"Estrogen receptor-alpha phosphorylated at Ser118 is present at the promoters of estrogen-regulated genes and is not altered due to HER-2 overexpression","volume":"66","author":"Weitsman","year":"2006","journal-title":"Cancer Res"},{"issue":"17","key":"10.1016\/j.phrs.2023.106806_bib78","doi-asserted-by":"crossref","first-page":"15413","DOI":"10.1074\/jbc.M111.225946","article-title":"Cellular iron depletion stimulates the JNK and p38 MAPK signaling transduction pathways, dissociation of ASK1-thioredoxin, and activation of ASK1","volume":"286","author":"Yu","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2023.106806_bib79","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/bies.10204","article-title":"Activation of the JNK signaling pathway: breaking the brake on apoptosis","volume":"25","author":"Lin","year":"2003","journal-title":"Bioessays"},{"issue":"2","key":"10.1016\/j.phrs.2023.106806_bib80","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1038\/modpathol.2010.55","article-title":"Issues and updates: evaluating estrogen receptor-\u03b1, progesterone receptor, and HER2 in breast cancer","volume":"23","author":"Allred","year":"2010","journal-title":"Mod. Pathol."},{"issue":"5","key":"10.1016\/j.phrs.2023.106806_bib81","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/j.1460-2075.1990.tb08280.x","article-title":"Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B","volume":"9","author":"Kastner","year":"1990","journal-title":"EMBO J."},{"issue":"18","key":"10.1016\/j.phrs.2023.106806_bib82","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.7150\/ijms.51176","article-title":"Estrogen receptor alpha\/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas","volume":"17","author":"Xiao","year":"2020","journal-title":"Int J. Med Sci."},{"issue":"6","key":"10.1016\/j.phrs.2023.106806_bib83","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1210\/endo-120-6-2597","article-title":"Estrogen down-regulation of androgen receptors in cultured human mammary cancer cells (MCF-7)","volume":"120","author":"Stover","year":"1987","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.phrs.2023.106806_bib84","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10549-005-9070-2","article-title":"Bidirectional cross talk between ER\u03b1 and EGFR signalling pathways regulates tamoxifen-resistant growth","volume":"96","author":"Britton","year":"2006","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.phrs.2023.106806_bib85","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1023\/A:1025484908380","article-title":"Oestrogen receptor-mediated modulation of the EGFR\/MAPK pathway in tamoxifen-resistant MCF-7 cells","volume":"81","author":"Hutcheson","year":"2003","journal-title":"Breast Cancer Res Treat."},{"issue":"6","key":"10.1016\/j.phrs.2023.106806_bib86","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.molmed.2015.04.001","article-title":"EGFR and NF-\u03baB: partners in cancer","volume":"21","author":"Shostak","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.phrs.2023.106806_bib87","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1371\/journal.pone.0114419","article-title":"MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2\u039416 mediated breast tumorigenesis and reverse trastuzumab resistance","volume":"9","author":"Huynh","year":"2014","journal-title":"PloS One"},{"issue":"16","key":"10.1016\/j.phrs.2023.106806_bib88","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1038\/onc.2013.154","article-title":"Macrophages stimulate gastric and colorectal cancer invasion through EGFR Y 1086, c-Src, Erk1\/2 and Akt phosphorylation and smallGTPase activity","volume":"33","author":"Cardoso","year":"2014","journal-title":"Oncogene"},{"issue":"Supplement_1","key":"10.1016\/j.phrs.2023.106806_bib89","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1677\/erc.1.01005","article-title":"Epidermal growth factor receptor\/HER2\/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer","volume":"12","author":"Gee","year":"2005","journal-title":"Endocr. -Relat. Cancer"},{"issue":"6","key":"10.1016\/j.phrs.2023.106806_bib90","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0960-9776(03)00137-1","article-title":"Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer","volume":"12","author":"Osborne","year":"2003","journal-title":"Breast"},{"issue":"10","key":"10.1016\/j.phrs.2023.106806_bib91","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1111\/bph.14985","article-title":"Overcoming tamoxifen resistance in oestrogen receptor-positive breast cancer using the novel thiosemicarbazone anti-cancer agent, DpC","volume":"177","author":"Maqbool","year":"2020","journal-title":"Br. J. Pharm."},{"issue":"2","key":"10.1016\/j.phrs.2023.106806_bib92","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088754","article-title":"Quantitative analysis of the anti-proliferative activity of combinations of selected iron-chelating agents and clinically used anti-neoplastic drugs","volume":"9","author":"Potuckova","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2023.106806_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2022.130152","article-title":"The thiosemicarbazone, DpC, broadly synergizes with multiple anti-cancer therapeutics and demonstrates temperature- and energy-dependent uptake by tumor cells","volume":"1866","author":"Dharmasivam","year":"2022","journal-title":"Biochim Biophys. Acta Gen. Subj."},{"issue":"2","key":"10.1016\/j.phrs.2023.106806_bib94","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1021\/acs.jmedchem.2c01600","article-title":"Designing tailored thiosemicarbazones with bespoke properties: the styrene moiety imparts potent activity, inhibits heme centre oxidation, and results in a novel \u201cStealth Zinc(II) complex\u201d","volume":"66","author":"Dharmasivam","year":"2023","journal-title":"J. Med Chem."},{"issue":"1","key":"10.1016\/j.phrs.2023.106806_bib95","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1124\/mol.112.078964","article-title":"Methemoglobin formation by triapine, di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT), and other anticancer thiosemicarbazones: identification of novel thiosemicarbazones and therapeutics that prevent this effect","volume":"82","author":"Quach","year":"2012","journal-title":"Mol. Pharm."},{"issue":"7","key":"10.1016\/j.phrs.2023.106806_bib96","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"issue":"1","key":"10.1016\/j.phrs.2023.106806_bib97","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"issue":"3","key":"10.1016\/j.phrs.2023.106806_bib98","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nmeth.2832","article-title":"Functional annotation of noncoding sequence variants","volume":"11","author":"Ritchie","year":"2014","journal-title":"Nat. Methods"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823001627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823001627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:34:56Z","timestamp":1778582096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661823001627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":98,"alternative-id":["S1043661823001627"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2023.106806","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovative thiosemicarbazones that induce multi-modal mechanisms to down-regulate estrogen-, progesterone-, androgen- and prolactin-receptors in breast cancer","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2023.106806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106806"}}